SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 12, 2003
Savient Pharmaceuticals, Inc.
(Exact name of issuer as specified in its charter)
Delaware | | 0-15313 | | 13-3033811 |
(State or Other Jurisdiction | | (Commission File Number) | | (IRS Employer |
of Incorporation) | | | | Identification No.) |
One Tower Center, 14th Floor | | |
East Brunswick, New Jersey | | 08816 |
(Address of Principal Executive Offices) | | (Zip Code) |
Registrant’s telephone number, including area code: (732) 418-9300
None.
(Former Name or Former Address, if Changed Since Last Report.)
ITEM 7. | FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS. |
| | | | | | |
(c) | Exhibits. | | | | | |
| | | | | | |
| 99.1 | Transcript of the conference call discussing Savient Pharmaceuticals, Inc.’s earnings results for the three and nine months ended September 30, 2003 held on November 12, 2003. |
| | |
| | |
ITEM 9. | REGULATION FD DISCLOSURE. |
| | | | | | | |
Filed herewith as Exhibit 99.1 is a transcript of the conference call discussing Savient Pharmaceuticals, Inc.’s earnings results for the three and nine months ended September 30, 2003 held on November 12, 2003.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | |
| | | | SAVIENT PHARMACEUTICALS, INC. |
| | | | (Registrant) |
| | | | |
| | | | |
| | | | By: | /s/ Whitney K. Stearns, Jr. | |
| | | | | Whitney K. Stearns, Jr. |
| | | | | Senior Vice President–Chief Financial Officer and Treasurer |
Dated: November 12, 2003
3
